Literature DB >> 28242667

In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.

Ryan K Shields1,2, M Hong Nguyen3,2, Ellen G Press1, Liang Chen4, Barry N Kreiswirth4, Cornelius J Clancy1,2,5.   

Abstract

Ceftazidime-avibactam resistance is mediated by blaKPC-3 mutations, which restore carbapenem susceptibility. We subjected Klebsiella pneumoniae isolates with different blaKPC-3 mutations (n = 5) or wild-type blaKPC-3 (n = 2) to serial passages with meropenem. The meropenem MIC against each isolate increased. Mutations in the ompK36 porin gene evolved in 5 isolates. Among isolates with D179Y substitutions in KPC-3, blaKPC-3 mutations reverted to wild type, were replaced by new mutations, or were retained. Carbapenem treatment of ceftazidime-avibactam-resistant K. pneumoniae infections may select for carbapenem resistance.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  KPC mutations; Klebsiella pneumoniae carbapenemase; carbapenem-resistant Enterobacteriaceae; ceftazidime-avibactam resistance; sequence type 258 Klebsiella pneumoniae

Mesh：

Substances：

Year:  2017        PMID： 28242667      PMCID： PMC5404588          DOI： 10.1128/AAC.00079-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence.

Authors:  Yu-Kuo Tsai; Chang-Phone Fung; Jung-Chung Lin; Jiun-Han Chen; Feng-Yee Chang; Te-Li Chen; L Kristopher Siu
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.

Authors:  Cornelius J Clancy; Binghua Hao; Ryan K Shields; Liang Chen; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

3.  Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae.

Authors:  Sheila Adams-Sapper; Shantell Nolen; Grace Fox Donzelli; Mallika Lal; Kunihiko Chen; Livia Helena Justo da Silva; Beatriz M Moreira; Lee W Riley
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

4.  Contribution of outer membrane protein K36 to antimicrobial resistance and virulence in Klebsiella pneumoniae.

Authors:  Jiun-Han Chen; L K Siu; Chang-Phone Fung; Jung-Chung Lin; Kuo-Ming Yeh; Te-Li Chen; Yu-Kuo Tsai; Feng-Yee Chang
Journal:  J Antimicrob Chemother       Date:  2010-03-07       Impact factor: 5.790

5.  Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants.

Authors:  Liang Chen; José R Mediavilla; Andrea Endimiani; Marnie E Rosenthal; Yanan Zhao; Robert A Bonomo; Barry N Kreiswirth
Journal:  J Clin Microbiol       Date:  2010-12-01       Impact factor: 5.948

6.  Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2015-05-08       Impact factor: 5.790

7.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

8.  Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.

Authors:  Daniel J Wolter; Philip M Kurpiel; Neil Woodford; Marie-France I Palepou; Richard V Goering; Nancy D Hanson
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

9.  Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.

Authors:  Cornelius J Clancy; Liang Chen; Jae H Hong; Shaoji Cheng; Binghua Hao; Ryan K Shields; Annie N Farrell; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

Review 10.  Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding.

Authors:  Liang Chen; Barun Mathema; Kalyan D Chavda; Frank R DeLeo; Robert A Bonomo; Barry N Kreiswirth
Journal:  Trends Microbiol       Date:  2014-10-07       Impact factor: 17.079
View more
  31 in total

1.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 3.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 4.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Authors:  Stephanie Ho; Lynn Nguyen; Trang Trinh; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2019-09-09       Impact factor: 3.725

5.  Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase.

Authors:  Fabrice Compain; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.

Authors:  Marla J Giddins; Nenad Macesic; Medini K Annavajhala; Stephania Stump; Sabrina Khan; Thomas H McConville; Monica Mehta; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 8.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

9.  Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.

Authors:  Ryan K Shields; M Hong Nguyen; Binghua Hao; Ellen G Kline; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity.

Authors:  Linda Mueller; Amandine Masseron; Guy Prod'Hom; Tatiana Galperine; Gilbert Greub; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.